2 QUALITATIVE AND QUANTITATIVE COMPOSITION
New Zealand Data Sheet 16 October 2017 Lasix and Lasix High Dose- furosemide (frusemide) lasix-lasix-high-dose-ccdsv12-dsv15-16oct17 Page 1
Download 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
DRUG NAME: Carboplatin
www.bccancer.bc.caCarboplatin DRUG NAME: Carboplatin SYNONYM(S): CBDCA, JM8, NSC 241240 COMMON TRADE NAME(S): PARAPLATIN®, PARAPLATIN-AQ® CLASSIFICATION: Alkylating agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply.
Gem-Cisp: Gemcitabine/Cisplatin in Relapsed …
www.londoncanceralliance.nhs.ukReason for Update: Network Protocol Development Gemcitabine. should be used with caution in patients with impaired renal function: CrCl (ml/min) Gemcitabine Dose
Protocol: Carboplatin/Gemcitabine
www.midwesterncancercentre.ieDepartment of Medical Oncology Chemotherapy Protocols 3rd Edition 1 Protocol: Carboplatin/Gemcitabine Indications: Lung Cancer (non-small cell) - Advanced
Protocol: BEP 3-day (Bleomycin/Etoposide/Cisplatin)
www.midwesterncancercentre.ieDepartment of Medical Oncology Chemotherapy Protocols 3rd Edition 62 Protocol: BEP 3-day (Bleomycin/Etoposide/Cisplatin) ...
LESSON ASSIGNMENT LESSON 6 Drugs Used to …
www.sweethaven02.comMD0913 6-3 c. Cautions and Warnings. (1) This drug should be used cautiously in pregnant women because of the fact that it can cross the placenta and cause ototoxicity (see d (1) below) in the fetus.
GENETIS LAORATORY TEST REQUEST FORM - …
shodair.orgShodair hildren’s Hospital Genetics Laboratory 2755 olonial Dr, Helena. MT, 59601 Phone (406) 444-7532 Toll Free (800) 447-6614 Fax (406) 444-1022 email: mtgene@shodair.org
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.pharma.us.novartis.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TOBI Podhaler safely and effectively. See full prescribing information for TOBI